Netupitant/Palonosetron

DRUG4 trials

Conditions

Chemotherapy-Induced Nausea and VomitingChemotherapy-induced Nausea and Vomiting

Phase 2

NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

CompletedNCT03862144

Consorzio OncotechChemotherapy-induced Nausea and Vomiting

Start: 2016-05-12End: 2017-04-03Updated: 2019-03-05

Phase 3

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

CompletedNCT02517021

Helsinn Healthcare SAChemotherapy-Induced Nausea and Vomiting

Start: 2015-11-30End: 2016-08-31Updated: 2018-06-20

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

CompletedNCT03403712

Helsinn Healthcare SAChemotherapy-induced Nausea and Vomiting

Start: 2018-03-16End: 2018-09-19Updated: 2020-06-01

Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin

NCT04201769

Consorzio OncotechChemotherapy-induced Nausea and Vomiting

Start: 2016-11-25End: 2020-04-30Updated: 2020-04-03

2024-03-04

Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study

Journal of Geriatric Oncology2023-06-076 citations

Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)

Scientific Reports2023-01-236 citations

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

BMC Cancer2022-08-2313 citations

Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by high-dose cisplatin.

Journal of Clinical Oncology2021-05-201 citations

Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.

Journal of Clinical Oncology2020-05-205 citations

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

BMC Cancer2020-03-1911 citations

Acute care and hydration due to chemotherapy-induced nausea and vomiting (CINV) among patients receiving NEPA prophylaxis for anthracycline + cyclophosphamide (AC).

Journal of Clinical Oncology2019-11-012 citations

Antiemetic efficacy of intravenous (IV) NEPA in patients with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy.

Journal of Clinical Oncology2019-11-01

Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).

Journal of Clinical Oncology2019-05-20

Efficacy of intravenous (IV) NEPA, a fixed NK<sub>1</sub>/5-HT<sub>3</sub> receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).

Journal of Clinical Oncology2018-11-28

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.

2018-07-0129 citations

Efficacy of an intravenous formulation of NEPA, a fixed combination of fosnetupitant and palonosetron, compared with oral NEPA studies in the prevention of chemotherapy-induced nausea and vomiting (CINV): An analysis of 1026 patient experiences.

Journal of Clinical Oncology2018-05-203 citations

Phase III safety evaluation of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles.

Journal of Clinical Oncology2017-11-013 citations

Netupitant/Palonosetron

Sponsors

Conditions

Phase 2

Phase 3

Related Papers